Lanreotide: Uses, Mechanism, Evidence, and Side Effects

Patients newly diagnosed with acromegaly or a neuroendocrine tumor often want to know how lanreotide fits into treatment and what to expect from it. Lanreotide is a long-established synthetic hormone analog with decades of clinical use and a defined FDA label.

Key takeaways

• Lanreotide is a somatostatin analog marketed as Lanreotide Acetate.
• It is FDA approved for acromegaly, certain gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome.
• More than 120 trials have been registered studying lanreotide across various uses.
• The most frequently reported adverse events in safety databases are gastrointestinal and general symptoms, including diarrhoea and fatigue.
• Lanreotide does not carry a boxed warning.

What Lanreotide Is

Lanreotide is an octapeptide analog of natural somatostatin, a hormone the body uses to regulate the release of other hormones. Its mechanism of action is believed to work similarly to natural somatostatin, tempering the secretion of substances like growth hormone and certain gut hormones. It is available under the brand name Lanreotide Acetate.

What Lanreotide Is Approved For

Lanreotide has three approved uses. It is indicated for long-term treatment of acromegaly in patients who have had an inadequate response to, or cannot undergo, surgery and/or radiotherapy. It is also approved for adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs, where it is used to improve progression-free survival. The third approved use is for adults with carcinoid syndrome, where lanreotide reduces how often patients need short-acting rescue therapy. No boxed warning is present on the label.

What the Evidence Shows

More than 120 clinical trials have been registered involving lanreotide, spanning its various indications and comparisons with related therapies. Among the trials in the available sample, a completed Phase 2 study examined lanreotide for preventing postoperative pancreatic fistula, and a completed Phase 4 study compared lanreotide Autogel with octreotide LAR on growth hormone and IGF-I levels along with patient satisfaction. A completed Phase 3 trial also studied lanreotide for preventing lymphorrhea following axillary dissection in breast cancer surgery.

Reported Side Effects

Safety reports submitted to FAERS for lanreotide most commonly describe gastrointestinal and general symptoms. Diarrhoea (1,415 reports), fatigue (972), nausea (725), and abdominal pain (568) rank among the most frequent terms, alongside injection site pain (596) and headache (502). Reports of death (1,221) and off-label use (1,461) also appear frequently in the data. These figures reflect the number of reports submitted, not confirmed incidence or a causal link to lanreotide.